Where Oncology MSL Teams Win: Reach, Quality, or Both?

Most oncology MSL teams compete on two dimensions: how many oncologists they reach, and how those oncologists rate the quality of those interactions. Few manufacturers lead on both at the same time.

Insights in this article are drawn from the ZoomRx Oncology Medical Engagement Perception Report 2026, a perception study of 51 US oncology specialists who interacted with at least one MSL team in the prior three months. Findings reflect oncologist-reported perceptions of MSL interactions, not internal company metrics.

The data behind this article comes from the 2026 ZoomRx perception study . When manufacturers are plotted by reach and interaction quality, distinct competitive profiles emerge. Knowing where your MSL team sits on that map is the starting point for any serious conversation about MSL strategy.

The reach-quality map

Reach reflects how many oncologists reported interacting with each manufacturer’s MSL team. Most reported interactions originated through direct outreach or conferences, though differences in reach may also reflect portfolio breadth, indication coverage, launch activity, and field investment.

Quality reflects something different: how oncologists rated the interaction once it happened. Scientific depth, responsiveness, relevance, trust, and engagement all shaped those ratings.

The contrast across manufacturers is striking.

AstraZeneca combines the broadest oncologist reach in the dataset with top-tier interaction quality. Roche/Genentech and Bayer post some of the strongest quality scores in the study, but within narrower reach footprints consistent with more focused oncology portfolios. Daiichi Sankyo and Eli Lilly reach above-average shares of oncologists but score below the field average on interaction quality, suggesting that visibility alone does not necessarily translate into meaningful scientific engagement.

Most manufacturers cluster in the middle: moderate reach, moderate quality, and limited separation from the competition.

Why both dimensions matter

Looking at reach alone misses half the picture.

High reach does not necessarily mean oncologists value the interaction. High quality within a narrow footprint does not necessarily translate into broader field presence.

The manufacturers separating most clearly in the dataset are positioned strongly across both dimensions.

That distinction matters because oncologists are not evaluating MSL teams based on activity counts. They are evaluating whether the interaction was scientifically valuable, clinically relevant, and worth continuing.

“Field presence shapes visibility. Interaction quality shapes how that visibility is remembered.”

What this means for manufacturers

Manufacturers sit in very different positions on this map. Each position calls for a different kind of action.

• Manufacturers with strong quality but narrower reach may need to evaluate whether their deployment model is limiting broader scientific engagement opportunities.
• Manufacturers with broad reach but weaker interaction ratings may have solved for visibility while leaving the interaction experience itself under-optimized.
• Manufacturers clustered near the middle face a different challenge: limited differentiation in an increasingly crowded oncology landscape.

The important question is not simply whether your MSL team is active. It is whether those interactions create meaningful scientific engagement relative to competing manufacturers.

How MET measures MSL engagement

ZoomRx’s Medical Engagement Effectiveness Tracker (MET) measures how HCPs perceive MSL engagement across field reach, interaction quality, scientific narrative effectiveness, and competitive standing within the market.

The findings in this article reflect one view from the broader MET framework: how manufacturers compare on reach and perceived interaction quality. MET also helps teams understand what drives engagement performance and how perceptions vary across brands, physician segments, practice settings, and therapy areas.

Internal activity metrics show what MSL teams did. MET shows how those interactions were experienced by HCPs.

If you are not sure where your MSL team sits on this map, you are making strategy decisions without the data to back them up. Get in Touch with us to see how MET measures physician-reported MSL impact across knowledge closure, research activation, scientific engagement, and competitive standing, and to explore a zero-cost MET pilot tailored to your field team.

Editorial note: All comparisons in this article are based on oncologist-reported perceptions from the ZoomRx Oncology Medical Engagement Perception Report 2026. Named manufacturer scores reflect how participating oncologists described their MSL interactions. A legal review is recommended before publication.